Zydus Cadila Readies Injectables Push
Building Pipeline Amid Tepid US Growth Outlook, As Remdesivir Launches In India
Executive Summary
Zydus Cadila expects domestic sales to improve and the US generics business to grow in “mid to high” single digits during FY21 after both saw a coronavirus-related hit in Q1. Meanwhile, approvals for a few biologics are expected, its COVID-19 vaccine candidate has just entered Phase II studies and the firm has just launched its Remdac version of remdesivir.
You may also be interested in...
India’s Saptagir Partners With Jubilant On Remdesivir
India’s Saptagir Laboratories has struck a deal with Jubilant Pharma to manufacture the ingredient for COVID-19 emergency treatment remdesivir. Meanwhile, following in the footsteps of Cipla, Hetero, Mylan and Zydus, Dr Reddy’s has launched its version of remdesivir for the Indian market under a licensing deal with Gilead.
Novavax-Serum Institute Seal Win-Win Deal For COVID-19 Vaccine
Novavax has granted Serum Institute rights to develop, manufacture and commercialize its COVID-19 vaccine candidate in selected regions, in another endorsement of the Indian group's capabilities. The agreement, which expands on an earlier association, gives Serum exclusive marketing rights in India until the deal ends and non-exclusive rights for developing countries to the end of the pandemic, with the US firm getting half of net revenue.
Merck Picks Up Hanmi’s Dual Agonist Efinopegdutide, But For NASH
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.